SELECT ?title WHERE { ?? (rdfs:label|skos:prefLabel|schema:name) ?title . } Squalen

SELECT ?class WHERE { ?? (rdf:type|owl:type) ?class . } DefinedTerm, Term, Validated Entry

SELECT ?description WHERE { ?? (rdfs:comment|schema:description) ?description . } Natürliches Zwischenprodukt des menschlichen endogenen Cholesterinstoffwechsels und Bestandteil der Körperzellen.

Attributes

Name

Squalen

squalene

squalène

squalene

Natürliches Zwischenprodukt des menschlichen endogenen Cholesterinstoffwechsels und Bestandteil der Körperzellen.

Description

Naturally occurring substance found in plants, animals, and humans.

Description

Substance que l'on trouve à l'état naturel dans certaines huiles animales - en particulier l'huile de foie de requin - et végétales et chez l'être humain.

Description

Composto secreto dal corpo umano per costruire ormoni steroidei ed altre sostanze lipidiche, essenziale per la sintesi di colesterolo.

dateModified

2024-06-03T08:35:25.4904100Z

Identifier

217801

URL

https://www.termdat.bk.admin.ch/entry/217801

citation

Paul-Ehrlich-Institut, Fachliche Information für Ärzte und Apotheker: Pandemieimpfstoffe in der Schwangerschaft, 2009-09-03 S. 2 ([Internet, 2020-06-22](https://www.pei.de/SharedDocs/Downloads/DE/arzneimittelsicherheit/pharmakovigilanz/090309-pandemieimpfstoffe-schwangerschaft.pdf?__blob=publicationFile&v=2))

citation

WHO, Vaccine Safety > The Global Advisory Committee on Vaccine Safety > Topics > Adjuvants > Squalene-based adjuvants in vaccines ([Internet, 2020-06-22](https://www.who.int/vaccine_safety/committee/topics/adjuvants/squalene/questions_and_answers/en/))

citation

OMS, Comité consultatif mondial sur la sécurité des vaccins > Comité consultatif mondial de la sécurité vaccinale (GACVS) > Sujets > Adjuvants > Adjuvants à base de squalène dans les vaccins ([Internet, 2020-06-22](https://www.who.int/vaccine_safety/committee/topics/adjuvants/squalene/questions_and_answers/fr/))

citation

IT, Ministero della Salute, Home > Risorse > Domande più frequenti > Vaccino “Cos’è lo squalene e perché viene usato come adiuvante nei vaccini?” ([Internet, 2020-06-22](http://www.nuovainfluenza.salute.gov.it/nuovainfluenza/dettaglioFaqNuovaInfluenza.jsp?id=131&area=influenzaAH1N1&paginaprovenienza=null&numeroFaq=12#12))

position

Linguistic Context

L'uso vaccinale dello squalene nasce dalle osservazioni che le emulsioni di sostanze lipidiche in acqua sono potenti stimolatori dell‟immunità innata.

Term Note

DOM: übertragbare Krankheiten; GRM: n.; EXP: Squalen wird in geringer Menge als Wirkverstärker (Adjuvans) in Impfstoffen verwendet

Term Note

DOM: communicable diseases; EXP: squalene is being added to improve the efficacy of several experimental vaccines including pandemic flu and malaria vaccines which are being developed

Term Note

DOM: maladies transmissibles; EXP: le squalène représente un constituant de certains adjuvants que l'on rajoute aux vaccins pour renforcer la réponse immunitaire

Term Note

DOM: malattie trasmissibili; EXP: alcuni vaccini sperimentali, inclusi dei vaccini anti-pandemia, vaccini anti-malarici e vari altri vaccini di natura virale e batterica, vengono allestititi con adiuvanti contenente lo squalene con l’obiettivo di rafforzare l’immunogenicità e quindi l’efficacia dei vaccini

termNoteCitation

WHO, Vaccine Safety >The Global Advisory Committee on Vaccine Safety > Topics > Adjuvants > Squalene-based adjuvants in vaccines ([Internet, 2020-06-22](https://www.who.int/vaccine_safety/committee/topics/adjuvants/squalene/questions_and_answers/en/))

termNoteCitation

Paul-Ehrlich-Institut, Newsroom > Veröffentlichungen zu Arzneimitteln > Sicherheitsinformationen (Human), Stellungnahme zu Risiken, die im Zusammenhang mit Squalen diskutiert werden: Squalen bzw. Squalen-Antikörper als angebliche Auslöser für das "Gulf war syndrome" ([Internet, 2020-07-07](https://www.pei.de/DE/newsroom/veroffentlichungen-arzneimittel/sicherheitsinformationen-human/archiv-infos-influenza-pandemie-2009-2010/sicherheit-12-11-2009-squalen.html))

termNoteCitation

d'après OMS, Comité consultatif mondial sur la sécurité des vaccins > Comité consultatif mondial de la sécurité vaccinale (GACVS) > Sujets > Adjuvants > Adjuvants à base de squalène dans les vaccins ([Internet, 2020-08-12](https://www.who.int/vaccine_safety/committee/topics/adjuvants/squalene/questions_and_answers/fr/))

termNoteCitation

ATS Sardegna, tipologie articoli >_descrizione categorie > vaccinazioni per l'influenza a h1n1 ([Internet, 2020-07-07](https://www.aslcarbonia.it/index.php?xsl=7&s=13907&v=2&c=232))

descriptionCitation

WHO, Vaccine Safety >The Global Advisory Committee on Vaccine Safety > Topics > Adjuvants > Squalene-based adjuvants in vaccines ([Internet, 2020-06-22](https://www.who.int/vaccine_safety/committee/topics/adjuvants/squalene/questions_and_answers/en/))

descriptionCitation

d'après OMS, Comité consultatif mondial sur la sécurité des vaccins > Comité consultatif mondial de la sécurité vaccinale (GACVS) > Sujets > Adjuvants > Adjuvants à base de squalène dans les vaccins ([Internet, 2020-06-22](https://www.who.int/vaccine_safety/committee/topics/adjuvants/squalene/questions_and_answers/fr/))

descriptionCitation

secondo IT, Istituto Superiore di Sanità ISS, Dipartimento di Malattie Infettive, Parassitarie ed Immunomediate, A. Cassone/G. Rezza, Influenza A e vaccinazione, gli esperti spiegano cos’è lo squalene, pag. 1 ([Internet, 2020-07-22](http://www.iss.it/binary/pres/cont/Squalene_1_.pdf))

Outgoing Relationships

property	object
seeAlso	vaccine
seeAlso	adjuvanted vaccine
seeAlso	adjuvant
inDefinedTermSet	Terminology of the communicable diseases
inDefinedTermSet	Swiss Federal Administration
Reliability code	Linguistic/formal check completed
termDomain	MEDICINE
termDomain	Health care

Incoming Relationships

property	subject
hyponym	adjuvant

Instances of this Class: No results found.

Superclasses of this Class: No results found.

Subclasses of this Class: No results found.

Raw data

{
  "ResourceIRI": "https://register.ld.admin.ch/termdat/217801",
  "QueryResults": {
    "incoming": {
      "Vars": [
        "property",
        "subject"
      ],
      "Bindings": [
        {
          "property": {
            "Type": "uri",
            "Value": "http://www.lexinfo.net/ontology/3.0/lexinfo#hyponym",
            "Lol": "hyponym"
          },
          "subject": {
            "Type": "uri",
            "Value": "https://register.ld.admin.ch/termdat/217800",
            "Lol": "adjuvant"
          }
        }
      ],
      "Error": ""
    },
    "instances": {
      "Vars": [
        "instance",
        "description"
      ],
      "Bindings": [],
      "Error": ""
    },
    "literals": {
      "Vars": [
        "property",
        "value"
      ],
      "Bindings": [
        {
          "property": {
            "Type": "uri",
            "Value": "http://schema.org/name",
            "Lol": "Name"
          },
          "value": {
            "Type": "literal",
            "Value": "Squalen",
            "Lol": "Squalen"
          }
        },
        {
          "property": {
            "Type": "uri",
            "Value": "http://schema.org/name",
            "Lol": "Name"
          },
          "value": {
            "Type": "literal",
            "Value": "squalene",
            "Lol": "squalene"
          }
        },
        {
          "property": {
            "Type": "uri",
            "Value": "http://schema.org/name",
            "Lol": "Name"
          },
          "value": {
            "Type": "literal",
            "Value": "squalène",
            "Lol": "squalène"
          }
        },
        {
          "property": {
            "Type": "uri",
            "Value": "http://schema.org/name",
            "Lol": "Name"
          },
          "value": {
            "Type": "literal",
            "Value": "squalene",
            "Lol": "squalene"
          }
        },
        {
          "property": {
            "Type": "uri",
            "Value": "http://schema.org/description",
            "Lol": "Description"
          },
          "value": {
            "Type": "literal",
            "Value": "Natürliches Zwischenprodukt des menschlichen endogenen Cholesterinstoffwechsels und Bestandteil der Körperzellen.",
            "Lol": "Natürliches Zwischenprodukt des menschlichen endogenen Cholesterinstoffwechsels und Bestandteil der Körperzellen."
          }
        },
        {
          "property": {
            "Type": "uri",
            "Value": "http://schema.org/description",
            "Lol": "Description"
          },
          "value": {
            "Type": "literal",
            "Value": "Naturally occurring substance found in plants, animals, and humans.",
            "Lol": "Naturally occurring substance found in plants, animals, and humans."
          }
        },
        {
          "property": {
            "Type": "uri",
            "Value": "http://schema.org/description",
            "Lol": "Description"
          },
          "value": {
            "Type": "literal",
            "Value": "Substance que l'on trouve à l'état naturel dans certaines huiles animales - en particulier l'huile de foie de requin - et végétales et chez l'être humain.",
            "Lol": "Substance que l'on trouve à l'état naturel dans certaines huiles animales - en particulier l'huile de foie de requin - et végétales et chez l'être humain."
          }
        },
        {
          "property": {
            "Type": "uri",
            "Value": "http://schema.org/description",
            "Lol": "Description"
          },
          "value": {
            "Type": "literal",
            "Value": "Composto secreto dal corpo umano per costruire ormoni steroidei ed altre sostanze lipidiche, essenziale per la sintesi di colesterolo.",
            "Lol": "Composto secreto dal corpo umano per costruire ormoni steroidei ed altre sostanze lipidiche, essenziale per la sintesi di colesterolo."
          }
        },
        {
          "property": {
            "Type": "uri",
            "Value": "http://schema.org/dateModified",
            "Lol": "dateModified"
          },
          "value": {
            "Type": "literal",
            "Value": "2024-06-03T08:35:25.4904100Z",
            "Lol": "2024-06-03T08:35:25.4904100Z"
          }
        },
        {
          "property": {
            "Type": "uri",
            "Value": "http://schema.org/identifier",
            "Lol": "Identifier"
          },
          "value": {
            "Type": "literal",
            "Value": "217801",
            "Lol": "217801"
          }
        },
        {
          "property": {
            "Type": "uri",
            "Value": "http://schema.org/URL",
            "Lol": "URL"
          },
          "value": {
            "Type": "literal",
            "Value": "https://www.termdat.bk.admin.ch/entry/217801",
            "Lol": "https://www.termdat.bk.admin.ch/entry/217801"
          }
        },
        {
          "property": {
            "Type": "uri",
            "Value": "http://schema.org/citation",
            "Lol": "citation"
          },
          "value": {
            "Type": "literal",
            "Value": "Paul-Ehrlich-Institut, Fachliche Information für Ärzte und Apotheker: Pandemieimpfstoffe in der Schwangerschaft, 2009-09-03 S. 2 ([Internet, 2020-06-22](https://www.pei.de/SharedDocs/Downloads/DE/arzneimittelsicherheit/pharmakovigilanz/090309-pandemieimpfstoffe-schwangerschaft.pdf?__blob=publicationFile\u0026v=2))",
            "Lol": "Paul-Ehrlich-Institut, Fachliche Information für Ärzte und Apotheker: Pandemieimpfstoffe in der Schwangerschaft, 2009-09-03 S. 2 ([Internet, 2020-06-22](https://www.pei.de/SharedDocs/Downloads/DE/arzneimittelsicherheit/pharmakovigilanz/090309-pandemieimpfstoffe-schwangerschaft.pdf?__blob=publicationFile\u0026v=2))"
          }
        },
        {
          "property": {
            "Type": "uri",
            "Value": "http://schema.org/citation",
            "Lol": "citation"
          },
          "value": {
            "Type": "literal",
            "Value": "WHO, Vaccine Safety \u003e The Global Advisory Committee on Vaccine Safety \u003e Topics \u003e Adjuvants \u003e Squalene-based adjuvants in vaccines  ([Internet, 2020-06-22](https://www.who.int/vaccine_safety/committee/topics/adjuvants/squalene/questions_and_answers/en/))",
            "Lol": "WHO, Vaccine Safety \u003e The Global Advisory Committee on Vaccine Safety \u003e Topics \u003e Adjuvants \u003e Squalene-based adjuvants in vaccines  ([Internet, 2020-06-22](https://www.who.int/vaccine_safety/committee/topics/adjuvants/squalene/questions_and_answers/en/))"
          }
        },
        {
          "property": {
            "Type": "uri",
            "Value": "http://schema.org/citation",
            "Lol": "citation"
          },
          "value": {
            "Type": "literal",
            "Value": "OMS, Comité consultatif mondial sur la sécurité des vaccins \u003e Comité consultatif mondial de la sécurité vaccinale (GACVS) \u003e Sujets \u003e Adjuvants \u003e Adjuvants à base de squalène dans les vaccins ([Internet, 2020-06-22](https://www.who.int/vaccine_safety/committee/topics/adjuvants/squalene/questions_and_answers/fr/))",
            "Lol": "OMS, Comité consultatif mondial sur la sécurité des vaccins \u003e Comité consultatif mondial de la sécurité vaccinale (GACVS) \u003e Sujets \u003e Adjuvants \u003e Adjuvants à base de squalène dans les vaccins ([Internet, 2020-06-22](https://www.who.int/vaccine_safety/committee/topics/adjuvants/squalene/questions_and_answers/fr/))"
          }
        },
        {
          "property": {
            "Type": "uri",
            "Value": "http://schema.org/citation",
            "Lol": "citation"
          },
          "value": {
            "Type": "literal",
            "Value": "IT, Ministero della Salute, Home \u003e Risorse \u003e Domande più frequenti \u003e Vaccino “Cos’è lo squalene e perché viene usato come adiuvante nei vaccini?” ([Internet, 2020-06-22](http://www.nuovainfluenza.salute.gov.it/nuovainfluenza/dettaglioFaqNuovaInfluenza.jsp?id=131\u0026area=influenzaAH1N1\u0026paginaprovenienza=null\u0026numeroFaq=12#12))",
            "Lol": "IT, Ministero della Salute, Home \u003e Risorse \u003e Domande più frequenti \u003e Vaccino “Cos’è lo squalene e perché viene usato come adiuvante nei vaccini?” ([Internet, 2020-06-22](http://www.nuovainfluenza.salute.gov.it/nuovainfluenza/dettaglioFaqNuovaInfluenza.jsp?id=131\u0026area=influenzaAH1N1\u0026paginaprovenienza=null\u0026numeroFaq=12#12))"
          }
        },
        {
          "property": {
            "Type": "uri",
            "Value": "http://schema.org/position",
            "Lol": "position"
          },
          "value": {
            "Type": "literal",
            "Value": "1",
            "Lol": "1"
          }
        },
        {
          "property": {
            "Type": "uri",
            "Value": "https://schema.ld.admin.ch/linguisticContext",
            "Lol": "Linguistic Context"
          },
          "value": {
            "Type": "literal",
            "Value": "L'uso vaccinale  dello squalene nasce dalle osservazioni che le emulsioni di sostanze lipidiche in acqua sono potenti stimolatori dell‟immunità innata.",
            "Lol": "L'uso vaccinale  dello squalene nasce dalle osservazioni che le emulsioni di sostanze lipidiche in acqua sono potenti stimolatori dell‟immunità innata."
          }
        },
        {
          "property": {
            "Type": "uri",
            "Value": "https://schema.ld.admin.ch/termNote",
            "Lol": "Term Note"
          },
          "value": {
            "Type": "literal",
            "Value": "DOM: übertragbare Krankheiten; GRM: n.; EXP: Squalen wird in geringer Menge als Wirkverstärker (Adjuvans) in Impfstoffen verwendet",
            "Lol": "DOM: übertragbare Krankheiten; GRM: n.; EXP: Squalen wird in geringer Menge als Wirkverstärker (Adjuvans) in Impfstoffen verwendet"
          }
        },
        {
          "property": {
            "Type": "uri",
            "Value": "https://schema.ld.admin.ch/termNote",
            "Lol": "Term Note"
          },
          "value": {
            "Type": "literal",
            "Value": "DOM: communicable diseases; EXP: squalene is being added to improve the efficacy of several experimental vaccines including pandemic flu and malaria vaccines which are being developed",
            "Lol": "DOM: communicable diseases; EXP: squalene is being added to improve the efficacy of several experimental vaccines including pandemic flu and malaria vaccines which are being developed"
          }
        },
        {
          "property": {
            "Type": "uri",
            "Value": "https://schema.ld.admin.ch/termNote",
            "Lol": "Term Note"
          },
          "value": {
            "Type": "literal",
            "Value": "DOM: maladies transmissibles;  EXP: le squalène représente un constituant de certains adjuvants que l'on rajoute aux vaccins pour renforcer la réponse immunitaire",
            "Lol": "DOM: maladies transmissibles;  EXP: le squalène représente un constituant de certains adjuvants que l'on rajoute aux vaccins pour renforcer la réponse immunitaire"
          }
        },
        {
          "property": {
            "Type": "uri",
            "Value": "https://schema.ld.admin.ch/termNote",
            "Lol": "Term Note"
          },
          "value": {
            "Type": "literal",
            "Value": "DOM: malattie trasmissibili;  EXP: alcuni vaccini sperimentali, inclusi dei vaccini anti-pandemia, vaccini anti-malarici e vari altri vaccini di natura virale e batterica, vengono allestititi con adiuvanti contenente lo squalene con l’obiettivo di rafforzare l’immunogenicità e quindi l’efficacia dei vaccini",
            "Lol": "DOM: malattie trasmissibili;  EXP: alcuni vaccini sperimentali, inclusi dei vaccini anti-pandemia, vaccini anti-malarici e vari altri vaccini di natura virale e batterica, vengono allestititi con adiuvanti contenente lo squalene con l’obiettivo di rafforzare l’immunogenicità e quindi l’efficacia dei vaccini"
          }
        },
        {
          "property": {
            "Type": "uri",
            "Value": "https://schema.ld.admin.ch/termNoteCitation",
            "Lol": "termNoteCitation"
          },
          "value": {
            "Type": "literal",
            "Value": "WHO, Vaccine Safety \u003eThe Global Advisory Committee on Vaccine Safety \u003e Topics \u003e Adjuvants \u003e Squalene-based adjuvants in vaccines  ([Internet, 2020-06-22](https://www.who.int/vaccine_safety/committee/topics/adjuvants/squalene/questions_and_answers/en/))",
            "Lol": "WHO, Vaccine Safety \u003eThe Global Advisory Committee on Vaccine Safety \u003e Topics \u003e Adjuvants \u003e Squalene-based adjuvants in vaccines  ([Internet, 2020-06-22](https://www.who.int/vaccine_safety/committee/topics/adjuvants/squalene/questions_and_answers/en/))"
          }
        },
        {
          "property": {
            "Type": "uri",
            "Value": "https://schema.ld.admin.ch/termNoteCitation",
            "Lol": "termNoteCitation"
          },
          "value": {
            "Type": "literal",
            "Value": "Paul-Ehrlich-Institut, Newsroom \u003e Veröffentlichungen zu Arzneimitteln \u003e Sicherheitsinformationen (Human), Stellungnahme zu Risiken, die im Zusammenhang mit Squalen diskutiert werden: Squalen bzw. Squalen-Antikörper als angebliche Auslöser für das \"Gulf war syndrome\"  ([Internet, 2020-07-07](https://www.pei.de/DE/newsroom/veroffentlichungen-arzneimittel/sicherheitsinformationen-human/archiv-infos-influenza-pandemie-2009-2010/sicherheit-12-11-2009-squalen.html))",
            "Lol": "Paul-Ehrlich-Institut, Newsroom \u003e Veröffentlichungen zu Arzneimitteln \u003e Sicherheitsinformationen (Human), Stellungnahme zu Risiken, die im Zusammenhang mit Squalen diskutiert werden: Squalen bzw. Squalen-Antikörper als angebliche Auslöser für das \"Gulf war syndrome\"  ([Internet, 2020-07-07](https://www.pei.de/DE/newsroom/veroffentlichungen-arzneimittel/sicherheitsinformationen-human/archiv-infos-influenza-pandemie-2009-2010/sicherheit-12-11-2009-squalen.html))"
          }
        },
        {
          "property": {
            "Type": "uri",
            "Value": "https://schema.ld.admin.ch/termNoteCitation",
            "Lol": "termNoteCitation"
          },
          "value": {
            "Type": "literal",
            "Value": "d'après OMS, Comité consultatif mondial sur la sécurité des vaccins \u003e Comité consultatif mondial de la sécurité vaccinale (GACVS) \u003e Sujets \u003e Adjuvants \u003e Adjuvants à base de squalène dans les vaccins ([Internet, 2020-08-12](https://www.who.int/vaccine_safety/committee/topics/adjuvants/squalene/questions_and_answers/fr/))",
            "Lol": "d'après OMS, Comité consultatif mondial sur la sécurité des vaccins \u003e Comité consultatif mondial de la sécurité vaccinale (GACVS) \u003e Sujets \u003e Adjuvants \u003e Adjuvants à base de squalène dans les vaccins ([Internet, 2020-08-12](https://www.who.int/vaccine_safety/committee/topics/adjuvants/squalene/questions_and_answers/fr/))"
          }
        },
        {
          "property": {
            "Type": "uri",
            "Value": "https://schema.ld.admin.ch/termNoteCitation",
            "Lol": "termNoteCitation"
          },
          "value": {
            "Type": "literal",
            "Value": "ATS Sardegna, tipologie articoli \u003e_descrizione categorie \u003e vaccinazioni per l'influenza a h1n1 ([Internet, 2020-07-07](https://www.aslcarbonia.it/index.php?xsl=7\u0026s=13907\u0026v=2\u0026c=232))",
            "Lol": "ATS Sardegna, tipologie articoli \u003e_descrizione categorie \u003e vaccinazioni per l'influenza a h1n1 ([Internet, 2020-07-07](https://www.aslcarbonia.it/index.php?xsl=7\u0026s=13907\u0026v=2\u0026c=232))"
          }
        },
        {
          "property": {
            "Type": "uri",
            "Value": "https://schema.ld.admin.ch/descriptionCitation",
            "Lol": "descriptionCitation"
          },
          "value": {
            "Type": "literal",
            "Value": "Paul-Ehrlich-Institut, Fachliche Information für Ärzte und Apotheker: Pandemieimpfstoffe in der Schwangerschaft, 2009-09-03 S. 2 ([Internet, 2020-06-22](https://www.pei.de/SharedDocs/Downloads/DE/arzneimittelsicherheit/pharmakovigilanz/090309-pandemieimpfstoffe-schwangerschaft.pdf?__blob=publicationFile\u0026v=2))",
            "Lol": "Paul-Ehrlich-Institut, Fachliche Information für Ärzte und Apotheker: Pandemieimpfstoffe in der Schwangerschaft, 2009-09-03 S. 2 ([Internet, 2020-06-22](https://www.pei.de/SharedDocs/Downloads/DE/arzneimittelsicherheit/pharmakovigilanz/090309-pandemieimpfstoffe-schwangerschaft.pdf?__blob=publicationFile\u0026v=2))"
          }
        },
        {
          "property": {
            "Type": "uri",
            "Value": "https://schema.ld.admin.ch/descriptionCitation",
            "Lol": "descriptionCitation"
          },
          "value": {
            "Type": "literal",
            "Value": "WHO, Vaccine Safety \u003eThe Global Advisory Committee on Vaccine Safety \u003e Topics \u003e Adjuvants \u003e Squalene-based adjuvants in vaccines  ([Internet, 2020-06-22](https://www.who.int/vaccine_safety/committee/topics/adjuvants/squalene/questions_and_answers/en/))",
            "Lol": "WHO, Vaccine Safety \u003eThe Global Advisory Committee on Vaccine Safety \u003e Topics \u003e Adjuvants \u003e Squalene-based adjuvants in vaccines  ([Internet, 2020-06-22](https://www.who.int/vaccine_safety/committee/topics/adjuvants/squalene/questions_and_answers/en/))"
          }
        },
        {
          "property": {
            "Type": "uri",
            "Value": "https://schema.ld.admin.ch/descriptionCitation",
            "Lol": "descriptionCitation"
          },
          "value": {
            "Type": "literal",
            "Value": "d'après OMS, Comité consultatif mondial sur la sécurité des vaccins \u003e Comité consultatif mondial de la sécurité vaccinale (GACVS) \u003e Sujets \u003e Adjuvants \u003e Adjuvants à base de squalène dans les vaccins ([Internet, 2020-06-22](https://www.who.int/vaccine_safety/committee/topics/adjuvants/squalene/questions_and_answers/fr/))",
            "Lol": "d'après OMS, Comité consultatif mondial sur la sécurité des vaccins \u003e Comité consultatif mondial de la sécurité vaccinale (GACVS) \u003e Sujets \u003e Adjuvants \u003e Adjuvants à base de squalène dans les vaccins ([Internet, 2020-06-22](https://www.who.int/vaccine_safety/committee/topics/adjuvants/squalene/questions_and_answers/fr/))"
          }
        },
        {
          "property": {
            "Type": "uri",
            "Value": "https://schema.ld.admin.ch/descriptionCitation",
            "Lol": "descriptionCitation"
          },
          "value": {
            "Type": "literal",
            "Value": "secondo IT, Istituto Superiore di Sanità ISS, Dipartimento di Malattie Infettive, Parassitarie ed Immunomediate, A. Cassone/G. Rezza, Influenza A e vaccinazione, gli esperti spiegano cos’è lo squalene, pag. 1 ([Internet, 2020-07-22](http://www.iss.it/binary/pres/cont/Squalene_1_.pdf))",
            "Lol": "secondo IT, Istituto Superiore di Sanità ISS, Dipartimento di Malattie Infettive, Parassitarie ed Immunomediate, A. Cassone/G. Rezza, Influenza A e vaccinazione, gli esperti spiegano cos’è lo squalene, pag. 1 ([Internet, 2020-07-22](http://www.iss.it/binary/pres/cont/Squalene_1_.pdf))"
          }
        }
      ],
      "Error": ""
    },
    "outgoing": {
      "Vars": [
        "property",
        "object"
      ],
      "Bindings": [
        {
          "object": {
            "Type": "uri",
            "Value": "https://register.ld.admin.ch/termdat/217788",
            "Lol": "vaccine"
          },
          "property": {
            "Type": "uri",
            "Value": "http://www.w3.org/2000/01/rdf-schema#seeAlso",
            "Lol": "seeAlso"
          }
        },
        {
          "object": {
            "Type": "uri",
            "Value": "https://register.ld.admin.ch/termdat/217791",
            "Lol": "adjuvanted vaccine"
          },
          "property": {
            "Type": "uri",
            "Value": "http://www.w3.org/2000/01/rdf-schema#seeAlso",
            "Lol": "seeAlso"
          }
        },
        {
          "object": {
            "Type": "uri",
            "Value": "https://register.ld.admin.ch/termdat/217800",
            "Lol": "adjuvant"
          },
          "property": {
            "Type": "uri",
            "Value": "http://www.w3.org/2000/01/rdf-schema#seeAlso",
            "Lol": "seeAlso"
          }
        },
        {
          "object": {
            "Type": "uri",
            "Value": "https://register.ld.admin.ch/termdat/INFEC20",
            "Lol": "Terminology of the communicable diseases"
          },
          "property": {
            "Type": "uri",
            "Value": "http://schema.org/inDefinedTermSet",
            "Lol": "inDefinedTermSet"
          }
        },
        {
          "object": {
            "Type": "uri",
            "Value": "https://register.ld.admin.ch/termdat/terminology-office/ACH",
            "Lol": "Swiss Federal Administration"
          },
          "property": {
            "Type": "uri",
            "Value": "http://schema.org/inDefinedTermSet",
            "Lol": "inDefinedTermSet"
          }
        },
        {
          "object": {
            "Type": "uri",
            "Value": "https://register.ld.admin.ch/termdat/reliability-code/2",
            "Lol": "Linguistic/formal check completed"
          },
          "property": {
            "Type": "uri",
            "Value": "https://schema.ld.admin.ch/reliabilityCode",
            "Lol": "Reliability code"
          }
        },
        {
          "object": {
            "Type": "uri",
            "Value": "https://register.ld.admin.ch/termdat/domain/5",
            "Lol": "MEDICINE"
          },
          "property": {
            "Type": "uri",
            "Value": "https://schema.ld.admin.ch/termDomain",
            "Lol": "termDomain"
          }
        },
        {
          "object": {
            "Type": "uri",
            "Value": "https://register.ld.admin.ch/termdat/sub-domain/39",
            "Lol": "Health care"
          },
          "property": {
            "Type": "uri",
            "Value": "https://schema.ld.admin.ch/termDomain",
            "Lol": "termDomain"
          }
        }
      ],
      "Error": ""
    },
    "pageClasses": {
      "Vars": [
        "class"
      ],
      "Bindings": [
        {
          "class": {
            "Type": "uri",
            "Value": "http://schema.org/DefinedTerm",
            "Lol": "DefinedTerm"
          }
        },
        {
          "class": {
            "Type": "uri",
            "Value": "https://schema.ld.admin.ch/Term",
            "Lol": "Term"
          }
        },
        {
          "class": {
            "Type": "uri",
            "Value": "https://schema.ld.admin.ch/ValidatedEntry",
            "Lol": "Validated Entry"
          }
        }
      ],
      "Error": ""
    },
    "pageSubtitle": {
      "Vars": [
        "description"
      ],
      "Bindings": [
        {
          "description": {
            "Type": "literal",
            "Value": "Natürliches Zwischenprodukt des menschlichen endogenen Cholesterinstoffwechsels und Bestandteil der Körperzellen.",
            "Lol": "Natürliches Zwischenprodukt des menschlichen endogenen Cholesterinstoffwechsels und Bestandteil der Körperzellen."
          }
        },
        {
          "description": {
            "Type": "literal",
            "Value": "Naturally occurring substance found in plants, animals, and humans.",
            "Lol": "Naturally occurring substance found in plants, animals, and humans."
          }
        },
        {
          "description": {
            "Type": "literal",
            "Value": "Substance que l'on trouve à l'état naturel dans certaines huiles animales - en particulier l'huile de foie de requin - et végétales et chez l'être humain.",
            "Lol": "Substance que l'on trouve à l'état naturel dans certaines huiles animales - en particulier l'huile de foie de requin - et végétales et chez l'être humain."
          }
        },
        {
          "description": {
            "Type": "literal",
            "Value": "Composto secreto dal corpo umano per costruire ormoni steroidei ed altre sostanze lipidiche, essenziale per la sintesi di colesterolo.",
            "Lol": "Composto secreto dal corpo umano per costruire ormoni steroidei ed altre sostanze lipidiche, essenziale per la sintesi di colesterolo."
          }
        }
      ],
      "Error": ""
    },
    "pageTitle": {
      "Vars": [
        "title"
      ],
      "Bindings": [
        {
          "title": {
            "Type": "literal",
            "Value": "Squalen",
            "Lol": "Squalen"
          }
        },
        {
          "title": {
            "Type": "literal",
            "Value": "squalene",
            "Lol": "squalene"
          }
        },
        {
          "title": {
            "Type": "literal",
            "Value": "squalène",
            "Lol": "squalène"
          }
        },
        {
          "title": {
            "Type": "literal",
            "Value": "squalene",
            "Lol": "squalene"
          }
        }
      ],
      "Error": ""
    },
    "subclasses": {
      "Vars": [
        "subclass",
        "description"
      ],
      "Bindings": [],
      "Error": ""
    },
    "superclasses": {
      "Vars": [
        "superclass",
        "description"
      ],
      "Bindings": [],
      "Error": ""
    }
  }
}

About